mirikizumab + tirzepatide

Mirikizumab + tirzepatide is a combination therapy being investigated for treating inflammatory bowel diseases (ulcerative colitis and Crohn's disease) in patients who also have obesity or are overweight.\n\nMirikizumab is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), inhibiting its inflammatory effects in inflammatory bowel diseases. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose, digestion, and appetite.\n\nThe combination aims to simultaneously address both the inflammatory aspects of bowel disease and metabolic issues related to obesity.